<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="biology-09-00141-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">biology-09-00141-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Details of vaccines under clinical trial.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Technical Platform</th>
    <th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Candidate Vaccine in Clinical Trial</th>
    <th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Developer</th>
    <th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Current Stage</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non Replicating Viral Vector</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">University of Oxford/AstraZeneca, Cambridge, U.K. /
     <break/>Serum Institute of India
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase2b/3 2020-001228-32 Phase 1/2 2020-001072-15</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non Replicating Viral Vector</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus Type 5 Vector</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">CanSino Biological Inc., China/Beijing Institute of Biotechnology, China</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid nanoparticles (LNP) encapsulated mRNA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderna Inc., USA/ National Institute of Allergy and Infectious Diseases (NIAID), USA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2 (IND submitted) Phase 1 NCT04283461</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Wuhan Institute of Biological Products, China/Sinopharm Group Co., Ltd., China</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2 ChiCTR2000031809</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Beijing Institute of Biological Products/ Sinopharm Group Co., Ltd., China</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2 ChiCTR2000032459</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated + Alum</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Sinovac Biotech Ltd., China </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2 NCT04383574 NCT04352608</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein Subunit</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Novavax Inc., Maryland, USA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2 NCT04368988</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">3 LNP-mRNAs</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BioNTech, Germany/Shanghai Fosun Pharmaceutical Co. Ltd., China /Pfizer, USA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2 2020-001038-36 NCT04368728</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Institute of Medical Biology, Chinese Academy of Medical Sciences</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA plasmid vaccine with electroporation </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Inovio Pharmaceuticals Inc., USA</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1 NCT04336410</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Note: 115 candidate vaccines are in preclinical evaluation. Information taken and adapted from DRAFT landscape of COVID-19 candidate vaccinesâ€”prepared by WHO [
    <xref rid="B52-biology-09-00141" ref-type="bibr">52</xref>].
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
